In-Depth Examination Of 11 Analyst Recommendations For Johnson & Johnson

11 analysts have expressed a variety of opinions on Johnson & Johnson JNJ over the past quarter, offering a diverse set of opinions from bullish to bearish.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $184.27, a high estimate of $215.00, and a low estimate of $167.00. This upward trend is apparent, with the current average reflecting a 2.82% increase from the previous average price target of $179.22.

Understanding Analyst Ratings: A Comprehensive Breakdown

The standing of Johnson & Johnson among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Johnson & Johnson. This insight gives a snapshot of analysts' perspectives on the current state of the company.
• Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Johnson & Johnson compared to the broader market.
• Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Johnson & Johnson's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.

For valuable insights into Johnson & Johnson's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on Johnson & Johnson analyst ratings.

All You Need to Know About Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

Financial Insights: Johnson & Johnson

Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.

Revenue Growth: Johnson & Johnson's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 2.34%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: Johnson & Johnson's net margin is impressive, surpassing industry averages. With a net margin of 15.22%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): Johnson & Johnson's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.69% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): Johnson & Johnson's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.92%, the company showcases efficient use of assets and strong financial health.

Debt Management: With a below-average debt-to-equity ratio of 0.48, Johnson & Johnson adopts a prudent financial strategy, indicating a balanced approach to debt management.

The Core of Analyst Ratings: What Every Investor Should Know

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga's automated content engine and reviewed by an editor.